



**Saving lives of
children with cancer
through excellence
in research, medical
care, and
education.**

This page is intentionally left blank

CONTENTS

About VIVA	4
Message from the Chairman	6
Exchanging Knowledge	7
Viva-University Children Cancer's Centre (VUC3)	
Viva-Goh Foundation Professorship in Paediatric Oncology	
Mrs Lee Kong Chian Chair in Advanced Cellular Therapy	
VIVA Centre of Translational Research in Acute Leukaemia (CENTRAL)	
VIVA-KKH Paediatric Brain and Solid Tumour Programme	
13th St. Jude-VIVA Forum on Paediatric Oncology	
Bridging Singapore, China and USA: Memorandum of Understanding	
Empowering Nurses through Training and Education	
Local and Regional Exchanges	
Gathering Communities	18
Fun Days Out with Childhood Cancer Survivors!	
Galvanising Corporate Support	
Raising Childhood Cancer Awareness in Schools	
Online Giving	
Bringing Year End Cheers to Childhood Cancer Patients	
VIVA in the Press	27
Financial Statements	29
Community Partnerships (Other Charity Funds)	32
Code of Governance	37
Board of Directors	39
External Advisory Board	41
To a Holistic Future for Survivors	42
Thank You	43

The VIVA Foundation for Children with Cancer was incorporated in Singapore on 6 February 2006 as Public Company Limited by Guarantee. It was registered under the Charities Act on 25 April 2006, with Institution of a Public Character (IPC) status.

UEN:	200601578E
Charity Registration No.:	01961
IPC Effective Period:	25 April 2006 – 14 May 2021
HEF Registration Number:	HEF 0105/G
Registered Address:	8 Sinaran Drive #03-01 Novena Specialist Center Singapore 307470
Chairman:	Mrs Jennifer Yeo (Mdm Leong Lai Peng)
Auditors:	Moore Stephens LLP
Bankers:	Citibank Singapore Ltd DBS Bank Ltd Oversea-Chinese Banking Corporation Ltd United Overseas Bank Ltd

S—V

FUNDING SOURCES

VIVA Foundation is financially supported by donations from members, donors and government grants.

VOLUNTEERING

VIVA Foundation is open to the public for participation in its charitable activities in aid of children with cancer.

STAFFING

As at 31 December 2019, there are three (3) full-time staff employed by VIVA Foundation.



OBJECTIVES

To help cure children with cancer so they can achieve the full potential of their lives by:



Partnering and funding scientists and doctors in key projects and clinical research



Supporting institutions to provide optimum facilities and level of care



Empowering doctors, nurses, and care-providers through training and knowledge-sharing

MESSAGE FROM THE CHAIRMAN



Every year, over 300,000 children across the world are diagnosed with cancer. In Singapore, as a small nation, that number is around 150 new diagnoses per annum, but this number doesn't count the existing patients who are in and out of treatment, the survivors, as well as the ones that have left us.

When VIVA was founded in 2006, our focus was to save more children with cancers by fostering systemic change through research, medical care and education.

In 2019, thanks to donors, partners, collaborators and volunteers, we were able to achieve some significant milestones.

In this report, you would read about a landmark Memorandum of Understanding between six International Partners to enable Singapore and Shanghai to be centres of excellence in paediatric oncology.

We expanded the 13th edition of our annual St. Jude-VIVA Forum in Paediatric Oncology, bringing together over 500 attendees to learn and collaborate with one another. In association with the Forum, we launched a Surgical Symposium and

a Nursing Institute, together with our longstanding partners the St. Jude Children's Research Hospital (USA), Singapore's National University Hospital and KK Women's and Children's Hospital.

Our hearts are warm with gratitude towards our diverse supporters and stakeholders—from youths and educators in school to corporate partners supporting VIVA through creative initiatives, showing that every bit counts.

In the following pages, you will also read about how students and faculty of the Singapore Chinese Girls School, Mayflower Secondary School, Greenwood Primary and APSN Chaoyang School joined hands with creative initiatives to support our mission to save lives of children with cancer. The value of our work was also affirmed by supporters such as the International Society for Pharmaceutical Engineering (ISPE), Colts Polo & Riding School and many more, who have generously contributed to our mission through their events.

I am humbled and honoured to have been awarded the Goodwill Ambassador Award by the Jiao Tong University School of Medicine for promoting academic collaborations between Shanghai and Singapore through our work at VIVA. It would not have been possible without the tireless work of our doctors, nurses, researchers, scientists and healthcare practitioners.

I am confident that with the continuing support of our industry partners, donors, and generous individuals, we can continue to give hope and rewrite the future for children with cancer.

Mrs Jennifer Yeo

Chairman

VIVA Foundation for Children with Cancers



EXCHANGING KNOWLEDGE

VIVA brings together doctors, scientists, nurses, and other medical professionals to share leading-edge research and collaborate for cures towards improving survival rates of childhood cancer in Singapore and the region.

VIVA-NUS CHILDHOOD CANCER PROGRAMME

VIVA-UNIVERSITY CHILDREN CANCER'S CENTRE (VUC³)

MEDICAL CARE (2019)

807 Inpatient admissions

12,168 Outpatient therapies

19 Bone marrow transplants

2 NK therapies

The VIVA-University Children's Cancer Centre (VUC³) is VIVA's first childhood cancer centre of excellence. The VUC³ provides a comprehensive childhood cancer treatment programme with capabilities of advanced cellular therapies and right siting of care with a 16-bed Day Therapy Centre for chemotherapy. It is housed at the National University Hospital (NUH).

VUC³ was built in 2008 and funded by VIVA through its donors, such as the Lee Foundation and Tote Board.

Together with the Goh Foundation and Children's Cancer Foundation translational clinical research funding, VUC³ has the capability to handle increasingly complex cases of childhood cancer from both Singapore and the surrounding region.

In 2019, the VUC³ continued its mission to provide excellent medical care for children with cancer, with 807 inpatient admissions and 12,168 outpatient therapies. Specialists at the VUC³ also conducted 15 CAR-T infusions, 19 bone marrow transplants, and 2 NK therapies over the course of the year.

VIVA-GOH FOUNDATION PROFESSORSHIP IN PAEDIATRIC ONCOLOGY



Associate Professor Allen Yeoh from the National University Singapore was appointed the VIVA-Goh Foundation Associate Professor in Paediatric Oncology in November 2012.

The professorship was created to advance paediatric oncology in strategic areas of childhood leukaemia, sarcoma, and childhood cancer survivorship.

It has also enabled Assoc Prof Yeoh to further the treatment of childhood cancer in Singapore and Asia through clinical research and clinician training, including leading-edge research into experimental treatments such as CAR-T cellular immunotherapy, among others.

Today, Assoc Prof Yeoh is highly recognised as a leader in Singapore and across Asia in the treatment of childhood leukaemia.


In 2019, he was awarded the National Medical Research Council of Singapore's **Clinician Scientist Award for Senior Investigator** for his work on the next generation sequencing platform at the Centre for Translational Research in Acute Leukaemia. He was also awarded the Singapore Ministry of Health **Distinguished Clinician Award** for his clinical impact on changing care for childhood and adult ALL in Singapore.

AWARDS (2019)

Clinician Scientist Award for a Senior Investigator
National Medical Research Council of Singapore

Distinguished Clinician Award
Singapore Ministry of Health

MRS LEE KONG CHIAN CHAIR IN ADVANCED CELLULAR THERAPY



AWARDS (2019)

2019 Jacob and Louise Gabbay
Award in Biotechnology and
Medicine

MEDICAL CARE (2019)

15 Patients
successfully treated
with CAR-T cell
therapy

110+ Patients by 2030

EDUCATION (2019)

2 Papers published

VIVA began the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy with the support of the Lee Foundation, which supports renowned expert Professor Dario Campana and his team at the National University Hospital of Singapore to conduct research on cell-based therapy and clinical trials for breakthroughs in cancer treatment.

One such treatment is the experimental CAR-T cellular immunotherapy which was developed by the Chair Professor Campana, who recently won the prestigious 2019 Jacob and Louise Gabbay Award in Biotechnology and Medicine for his work.

For cancer patients who have reached the end of their treatment options, CAR-T cell therapy represents a new hope for life. Between 2018-2019, the VIVA programme successfully administered the first CAR-T cell therapy in

Singapore to ten cancer patients facing imminent death, being resistant to traditional cancer treatment. Since then, they have been "cancer-free" and are to date, in remission. Dr Campana and his team plan to conduct therapy trials for up to 100 patients in the next 5-10 years.

The promising work done under Mrs Lee Kong Chian Chair has also since unlocked over \$6M of additional research funding from the NCIS Cancer Centre, the Goh Foundation, the Lee Foundation, and the Children's Cancer Foundation, amongst others—ensuring that we can all continue the development of new cures that would enable doctors to save more lives for children with cancer.


VIVA is grateful for this on-going collaboration which has been on-going since the Chair's inception in 2013, and would also like to thank all our donors for their contributions to this programme.

Total funds raised for Mrs Lee Kong Chian Chair, VIVA-University
Children's Cancer Centre and VIVA-Goh Foundation Professorship

\$ 53,758,000*

* This figure includes funds raised by VIVA, NUHS, and matching government grants. Details are available on (A2) on p.33, (C1) on p.34, (C2) and (C3) on p.35.

VIVA-NUS CENTRE OF TRANSLATIONAL RESEARCH IN ACUTE LEUKAEMIA (CenTRAL)



In 2014, VIVA set up the **VIVA-NUS Centre for Translational Research in Acute Leukaemia (CenTRAL)** in collaboration with the National University of Singapore. CenTRAL was established to make significant advances to risk classification, treatment monitoring, and to develop novel therapies to improve cure rates of children and adults with acute lymphoblastic leukaemia (ALL).

The facility is led by VIVA-Goh Foundation Assoc Prof Allen Yeoh and Mrs Lee Kong Chian Chair Prof Dario Campana from the NUS School of Medicine.

Since its inception, CenTRAL was able to conduct some 2,554 molecular tests for childhood cancer patients, which due to its complexity are not available in standard laboratories in Singapore. The tests enabled doctors to better determine the best levels of treatment, with 80% of patients receiving less chemotherapy, less side effects, improving their chances for cure.

In 2019, CenTRAL was awarded the Singapore Accreditation Council SINGCLASS Accredited

Laboratory Mark—the first university-based laboratory in Singapore to do so—enhancing its credibility and assuring the public that services are conducted in line with globally-recognised standards. Aside from this, six laboratory tests developed by CenTRAL were also accredited by the SAC as fulfilling ISO 15189 requirements.

Since VIVA's establishment in 2006, we have been supporting the Malaysia-Singapore Acute Lymphoblastic Leukaemia (ALL) Study. CenTRAL's molecular testing in children with ALL is the world's first clinical trial incorporating the IKZF1 gene risk assignment as identified from the study. This has resulted in an improvement in cure rates and delivered one of the best ALL treatment outcomes in the world—a drop in relapse rates from 30.4% to 13.5%. CenTRAL will continue this study in 2020 for the next five years, after successfully clinching additional funding from the highly competitive National Medical Research Council grant in 2019.

ACCREDITATION (2019)

- ✓ Laboratory tests accredited by the Singapore Accreditation Council as fulfilling base requirements for ISO 15189
- ✓ First university-based laboratory in Singapore to receive SingClass accredited laboratory mark

TOTAL FUNDS RAISED FOR THIS PROGRAMME

\$ 7,772,099*

* This figure includes funds raised by: VIVA (\$7,730,202) and partner (\$21,897).

VIVA-KKH PAEDIATRIC BRAIN AND SOLID TUMOUR PROGRAMME

Despite advances in the treatment of paediatric cancers, outcomes for most childhood solid tumours remain inferior to blood cancers.

Established in 2015, the **VIVA-KKH Paediatric Brain and Solid Tumour Programme** is a collaborative clinical and research partnership between VIVA, KK Women's and Children's Hospital (KKH), and St. Jude Children's Research Hospital to seek advancements in childhood brain and solid tumours by improving clinical care, translational research, education, and leveraging the expertise and strength of partner institutions.

Even though the pilot programme ended in 2018, the advancements made during the collaboration continues to benefit a wider public. New diagnostic tests were developed and rolled out across Singapore and the region. Patients received improved medical care through a multi-disciplinary brain tumour clinic providing a one-stop outpatient services,

which continues to run today. Doctors were able to improve their medical knowledge through new research collaborations, regional exchanges, academic presentations, and researches published.

In 2019, the programme launched a regional Fellowship in paediatric surgical oncology and pathology to address the gap in skilled professionals in countries that need them most—such as in Cambodia, China, Malaysia, and Pakistan.

The Fellowship under this programme will last for two years from 2019 to 2021. The programme successfully clinched an additional 14 grants worth over \$3.3M, which will enable medical professionals to further expand and build upon the developments made during the course of the collaboration. VIVA thanks the Children's Cancer Foundation and all our donors for their contributions to this programme.



Brain and solid tumours make up over half of all childhood cancers and account for the majority of malignant deaths in children. Their treatment is complex, and requires coordinated efforts from a whole team of diverse medical subspecialties.

—Dr Amos Loh
Chairman, Steering Committee,
VIVA-KKH
Paediatric Brain and Solid Tumour Programme



TOTAL FUNDS RAISED FOR THIS PROGRAMME

\$ 26,208,937*

* This figure includes the seed funding of \$8,200,000 raised by VIVA and additional funds from partners and government matching.



Paediatric Brain and Solid Tumours Awareness Day

23 Mar 2019

The PBSTA Programme, which began in 2014, has since grown in its awareness and funds in support of childhood cancer. A student-led initiative by Duke-NUS Medical School, VIVA has been invited to attend the Paediatric Brain Solid Tumour Awareness Day yearly.

In 2019, PBSTA was held at Marina Barrage and the students put together a day of activities for childhood survivors of brain and solid tumours. They were supported by Adj Assoc Prof Ng Kee Chong, Chairman Medical Board, KKH and

Assoc Prof David Low, Head of Neurosurgery and Senior Consultant at the National Neuroscience Institute (TTSH and KKH campuses respectively).

VIVA thanks Duke-NUS Medical School for supporting their students in organising this meaningful activity as well as Porsche Club Singapore, Yakult Singapore, and Pirelli Asia Singapore Pte Ltd for supporting this event.

13th ST. JUDE-VIVA FORUM ON PAEDIATRIC ONCOLOGY

28 Feb – 3 Mar 2019



SJVF 2019 IN NUMBERS

500+ Participants

25 Countries

31 Partners

13th Edition

The St. Jude-VIVA Forum in Paediatric Oncology is regarded as one of the leading paediatric oncology conferences in the region, providing medical professionals in Asia with the opportunity to learn and network with each other and to foster collaborations. It is organised annually with the combined efforts of VIVA and the St. Jude Children's Research Hospital (Memphis, Tennessee, USA), key local partners including the KK Women's and Children's Hospital, the National University Hospital and main sponsor the Goh Foundation.

The SJVF features a series of knowledge exchange platforms and collaborative meetings including the VIVA Asia Pre-Forum Workshop, the VIVA Asia Nursing Symposium, the VIVA Asia Bone Marrow Transplant Spring School, the CCF-VIVA Family Learning Exchange, and the VIVA Asia Working Groups. These meetings enable medical practitioners, from doctors to nurses, scientists to clinicians, to share leading-edge research with each other and team up to create cross-border collaborations in order to save more lives.

The annual attendance for SJVF has grown. In 2019, SJVF welcomed over 500 participants from across 25 countries, including 29 Medical and Nursing Travelling Fellows supported by VIVA, Protostar Foundation, and Miltenyi Biotec, as well as a delegation of over 30 doctors from China supported by Kindstar.

In 2019, the SJVF also launched two new initiatives: the St. Jude-VIVA Paediatric Surgical Symposium and the St. Jude-VIVA Asia-Pacific Nursing Institute, bringing together surgeons and nurses from the region to learn from each other. The first-ever Celebratory Dinner was also organised alongside SJVF, bringing together 600 conference participants, VIVA partners, donors, supporters, volunteers, patients, survivors, and their families.

VIVA would like to thank the Organising Committee comprising doctors, nurses and administrators from the Netherlands, the Philippines, Singapore and USA.



SJVF PROGRAMME

St. Jude-VIVA Paediatric Surgical Symposium

VIVA Asia Pre-Forum Workshop

VIVA Asia Nursing Symposium

VIVA Asia Bone Marrow Transplant Spring School

CCF-VIVA Family Learning Exchange

Working Group Meetings for Leukaemia, Brain & Solid Tumours, and Bone Marrow Transplant

VIVA Celebratory Dinner



The St. Jude-VIVA Forum brings together the world's top oncologists, nurses, allied medical professionals. In 2019, the SJVF welcomed over 500 delegates across 25 countries, as well as welcomed special Guest of Honour Minister of Foreign Affairs Vivian Balakrishnan and VIVA Goodwill Ambassador and Olympic Medallist Joseph Schooling, Donors, Corporate Partners, Patients, and Volunteers!

BRIDGING SINGAPORE, CHINA AND USA: MEMORANDUM OF UNDERSTANDING



Six organisations from Singapore, Shanghai, and the US sign a Memorandum of Understanding at the VIVA office in Singapore on 2 March 2019 to collaborate on boosting advancements in childhood cancer treatment.

MEMORANDUM PARTNERS

VIVA Foundation for Children with Cancer
Singapore

VIVA China Children's Cancer Foundation
Hong Kong

St. Jude Children's Research Hospital
Memphis, Tennessee, USA

KK Women's & Children's Hospital
Singapore

National University of Singapore
Singapore

Shanghai Children's Medical Center / National Children's Medical Center
Shanghai, China

VIVA brought together six organisations from USA, Shanghai and Singapore to sign a Memorandum of Understanding that aims to leverage Singapore and Shanghai as centres of excellence for research, clinical care, and treatment of children with cancer.

Under the MOU, the parties will find ways to collaborate in the training, of doctors, nurses, and other caregivers from Singapore, China, and Asia to provide better care, treatment, and follow up of children with cancer and survivors.

Through the collaboration, VIVA hopes to raise survivorship across Asia as doctors gain access to advancements in children's cancer research.



This agreement will help us leverage that success to advance training, medical treatment and research to more patients and their health care providers.

—Dr Carlos Rodriguez-Galindo

Executive Vice President and Chair, Department of Global Pediatric Medicine, St. Jude Children's Research Hospital



EMPOWERING NURSES THROUGH TRAINING AND EDUCATION



VIVA recognises that nursing care is a vital part of medical treatment for children with cancer. This is why since 2007, VIVA has been supporting training and education programmes for registered nurses to gain specialised knowledge and skills in order to deliver the best level of medical care.



VIVA Asia Nursing Symposium 1 Mar 2019

In its fifth year, the **VIVA-Asia Nursing Symposium** brings together nursing professionals from across the region to share experiences and techniques in caring for children with cancer. The theme for 2019 focused on "Care of the Immunocompromised Child".



St. Jude-VIVA Asia-Pacific Nursing Institute 1 Mar 2019

The St. Jude-VIVA Asia-Pacific Nursing Institute was launched at the 2019 St. Jude-VIVA Forum. The pilot programme included shared insights from nursing professionals across the region, intensive week-long hands-on training at the National University Hospital and the KK Women's and Children's Hospital (KKH) in Singapore, followed by monthly online sessions throughout the year.

The pilot programme was rolled out across two hospitals, namely the Philippines General Hospital in Manila and the Southern Philippines Medical Centre in Davao.



VIVA Nurses' Day Workshop 2 Aug 2019

To celebrate the daily heroes in hospital wards, VIVA brought together over 40 nurses from public and private institutions who work with children with cancer in Singapore for a one-day workshop.

The **VIVA Nurses' Day Workshop** featured a talk by NUS professor Quah Thuan Chong on the development of paediatric oncology in Singapore, and a session on using the arts for patient engagement and self-care with volunteers Ms Karen Koh and Ms Bethany Nette.

The workshop was sponsored by Novartis.

LOCAL AND REGIONAL EXCHANGES



Childhood Cancer Outreach

28 Feb 2019

In a talk with regional paediatric oncologists, VIVA's External Advisory Board Member Professor Anjo Veerman (Vrije Universiteit Medical Center, the Netherlands), together with Dr Eddy Supriyadi (Dr Sardjito Hospital, Indonesia) and Assoc Prof TC Quah (NUH), spoke on the past decade of development in the field of childhood cancer in the Netherlands, Indonesia, and beyond. *Held at the Hollandse Club, Singapore.*



Dialogue: The Changing Game Plan for Acute Lymphoblastic Leukaemia

23-24 May 2019

VIVA invited Professor Elias Jabbour of MD Anderson Cancer Centre in Houston USA to share with the Singapore community updates on treatment for patients with relapsed/refractory acute lymphoblastic leukaemia. *The visit was sponsored by AMGEN.*



Jiao Tong University Visit to Singapore

11 Aug 2019

The Shanghai Jiao Tong University School of Medicine presented the Love Ambassador Award to VIVA's Chairman, Mrs Jennifer Yeo, for her contribution in promoting academic collaborations between the Shanghai university and tertiary-level institutions in Singapore. VIVA appreciates and is encouraged by this award, and shares it with every collaborator, donor, and volunteer helping VIVA in its fight against childhood cancer.

The Award was part of a three-day visit programme led by Professor Chen Guoqiang to explore further collaborations with Singapore institutions.



4th Retinoblastoma & Ophthalmic Oncology Symposium at NUHS

24-25 Aug 2019

VIVA supported the 4th Retinoblastoma & Ophthalmic Oncology Symposium at the National University Health System. The regional symposium brought together about 130 healthcare professionals—from paediatric oncologists, ophthalmologists, nurses, pharmacists, optometrists, to exchange insights on supporting children with eye cancers and low vision.



Patient Advocacy Forum 29 Oct 2019

VIVA was invited by Novartis to moderate a panel discussion with local and international speakers on the role of the patients' voice and involvement in the healthcare ecosystem. We are very happy to have the opportunity to come together and learn together with the patient advocacy groups in Singapore.



Inaugural Asia Paediatric Oncology Leadership Meeting 20-22 Sep 2019, Davao City, Philippines

The Asia Childhood Cancer Alliance (ACCA) is a regional grouping of doctors and multisectoral collaborators from 12 countries to discuss common problems, share experiences and resources to improve survival cure for kids.

The ACCA normally meets on the sidelines of the SJVF in Singapore with a Strategic Meeting and the VIVA Asia Regional Education Day. From 2019 onwards, hospitals in the region will begin to host the ACCA Strategic Leadership Meeting on a rotational basis, marking a significant milestone to step up collaborative efforts in Asia.



The inaugural meeting was hosted in Davao City, the Philippines, by the House of Hope Foundation for Kids with Cancer in collaboration with the St. Jude Children's Research Hospital, the VIVA Foundation for Children with Cancer, with the support of the National University Hospital, Singapore, KK Women's and Children's Hospital, Singapore and Southern Philippines Medical Center.



St. Jude-VIVA-NCMCS Paediatric Haematology / Oncology Forum 9-11 Nov 2019, Guangzhou

A delegation from Southeast Asia, including representatives from VIVA, took part in the St. Jude-VIVA NCMCS Paediatric Haematology and Oncology Forum organised by the VIVA China Children's Cancer Foundation.

The SJVNF enables paediatric oncologists in China and the region to share the latest knowledge with leading practitioners in the world and the region, and foster collaborations to advance cures and save lives of more children with cancer.



GATHERING COMMUNITIES

VIVA brings together communities from different walks of life in support of childhood cancer—from fun social activities for patients, survivors, and their families, to public awareness campaigns and fundraising drives to support VIVA's mission to save more lives.

FUN DAYS OUT WITH CHILDHOOD CANCER SURVIVORS!



A Soaring Experience on Children's Day! 5 Oct 2019

For Children's Day, VIVA invited cancer survivors and families to come together for a soaring experience! For many, it was the first time to fly a drone. Everyone was able to bring home family portraits taken by drones in the air.

VIVA is thankful for the generosity of sponsors and supporters - Epson Singapore, Parrot, Singapore Hobby Supplies Pte Ltd, Skyhobbies Singapore Pte Ltd, Solomon Holistic Solutions Pte Ltd, and volunteers.



KAMP Music Festival 2019 9 Nov 2019

Lights, music, fun! In 2019, VIVA invited children and families affected by childhood cancer to enjoy a night of K-Pop at the 2019 KAMP Music Festival. Kids got to stay up late and had a blast during the evening.

VIVA is thankful for the generosity of Carrington RHT Wealth for enabling our families for a great evening filled with music!



VIVA Thanksgiving Art Competition 22 Oct – 18 Nov 2019

In 2019, VIVA held its first-ever Thanksgiving Art Competition to reflect and give thanks. With the theme "Gratitude", the competition welcomed submissions from children, youth, and adults alike who have been affected by cancer. This includes patients, survivors, siblings, and caregivers!

Submissions were featured in an exhibition held during VIVA's screening of Frozen II for childhood cancer survivors. VIVA warmly thanks all participants for their wonderful submissions.



Stories We Must Tell

16 Nov 2019

Cancer survivors Nadiah, Kieran, Ezri and Ivey contributed to this year's Birthday Book Jr entitled, "Stories we Must Tell".

VIVA organised a book launch and signing for these junior contributors, inviting fellow childhood cancer survivors and their families for a fun day out!



Giving Thanks Through Movies!

21 Nov 2019

Families—young and old—were treated to a fun night out with an exclusive screening of Frozen II and a sneak preview of artworks submitted for the VIVA Thanksgiving Art Competition.

VIVA is thankful for the generosity of Sparring Events, which sponsored the screening for over 30 families that evening!

GALVANISING CORPORATE SUPPORT



Kuok (Singapore) Limited Charity Golf and Dinner 4 Oct 2019

In 2019, VIVA was selected as one of the beneficiary charities of the Kuok (Singapore) Limited (KSL) Charity Drive, which included a Charity Golf Tournament and their 70th Anniversary Dinner. KSL raised \$275,000, with matching funds from the Singapore Tote Board, in support of VIVA from the event.

VIVA is grateful to KSL and their associates in supporting children with cancer through VIVA's programmes.

H.O.T Mama Women Achievers Award 2019 29 Oct 2019

In 2019, EcoreCom Branding organised a gala dinner in support of VIVA, which brought together mothers embracing and celebrating their talents and beauty. VIVA was also able to share about its work in raising survival rates for children with cancer. The Gala Dinner was able to raise \$20,832 in aid of VIVA's mission.

VIVA thanks EcoreCom Branding, their partners and supporters for organising the event!





ISPE Singapore Inaugural Charity Ball and Singapore Kindness Run 29 Mar 2019 and 3 Aug 2019

In 2019, the International Society for Pharmaceutical Engineering in Singapore (ISPE) raised \$12,010 in support of VIVA's mission to save more lives of children with cancer through several initiatives.

In March, ISPE brought over 100 of its members together for an evening of entertainment and charity during its inaugural Charity Ball. Some 14 members from ISPE also took part in the Singapore Kindness Run in August.


VIVA thanks ISPE President Joseph Micsko and his team for organising these initiatives in support of VIVA!



St Regis Polo Generations 2019 23 Nov 2019

St Regis Polo Generations adopted VIVA as its charity of choice in 2019. In a fun-filled day for survivors and families, kids caught polo matches, learned how to handle polo mallets, and played with colts!

VIVA thanks Patrick and Janine Furlong of Colts Polo & Riding School, as well as their partners and sponsors, for organising this event and raising \$20,172 in support of VIVA's mission.



We are humbled to work with the VIVA Foundation and add our support to their mission. Ours is but a small contribution when compared to the incredible work VIVA does in saving children's lives. We will be blessed to work with VIVA again in the future!

—Patrick Furlong
Colts Polo & Riding School

RAISING CHILDHOOD CANCER AWARENESS IN SCHOOLS



Bloom: A Celebration of Youth and Charity 29 May - 1 Jun 2019



Bloom 2019 celebrated Hope and Love to support kids with cancer in an inspiring show filled with music, theatre, and the arts! Organised by teachers and performed by students of the Singapore Chinese Girls' School, Bloom brought together youth, talent, and courage raise over \$34,517 in support of VIVA's mission to save more lives of children with cancer.

VIVA thanks the Singapore Chinese Girls School community for their inspiring teamwork and commitment to VIVA's mission, the Lee Kong Chian School of Medicine and Mayflower Secondary School, donors, and volunteers for their support, time, and resources in making this concert happen.

Promoting Awareness of Childhood Cancer: Values in Action Project with Mayflower School

24 Jul 2019

Inspired by their participation in the Bloom charity concert, students from the Mayflower Secondary School chose to support VIVA through their Values in Action project. Featuring presentations by students and insights from VIVA Asia Nursing Symposium organising committee member and KKH nurse Lim Yan Yin, the project raised awareness about childhood cancer amongst youths and peers.

VIVA thanks the organisers of this project, including Mrs Ess, students Signe Ye and Choo Guan Xi for supporting our mission!



Greenwood Secondary and APSN Chaoyang School Donate to Viva

2 Aug 2019 / 10 Oct 2019

Greenwood Primary School, in partnership with APSN Chaoyang School, chose VIVA as the main beneficiary of their annual fundraiser carnival in 2019. The carnival raised \$12,968 in aid of VIVA. VIVA is grateful to students and teachers from both schools for their dedication!



International Childhood Cancer Awareness Day

5 Feb 2019

To commemorate International Childhood Cancer Day, VIVA partnered the National University of Singapore (NUS) Life Sciences Society to organise a dialogue on paediatric oncology for university students. The talk welcomed VIVA's longstanding collaborators, Associate Professor Allen Yeoh from the National University Hospital and Dr David Low from KK Women's and Children's Hospital to share their inspiring journeys and contributions towards advancing childhood cancer cures.

Tanglin Trust PTA Donates to VIVA

The Parent Teacher Association of the Tanglin Trust School raised \$5,277 in aid of VIVA in a very well-attended Quiz Night! VIVA is grateful to the Tanglin Trust PTA for raising funds in aid of our mission.



Gongshang Primary School Donates to VIVA

As part of Gongshang Primary School's Values in Action programme to nurture students to become responsible citizens, Primary 6 students chose VIVA to be the recipient of proceeds for their annual Entrepreneur Bazaar. VIVA is very thankful to Gongshang's Primary 6 students, who raised \$10,280 to save children with cancer!

ONLINE GIVING



VIVA thanks our generous individual donors who have contributed to support VIVA's mission via online platform Giving.sg! We also thank the following supporters who organised online fundraising campaigns in aid of VIVA.

LKC is turning 9 in 2019

Laughing Kookaburra Corner

Laughing Kookaburra Corner raised \$11,420 on the occasion of their 9th anniversary to enable kids with cancer to chase their dreams and make them a reality.

Cherish My Children

Cherish Academy

Cherish Academy raised \$248 to support children and families who have experienced emotional and financial difficulties as a result of childhood cancer.

Saba's initiative to help children with cancer

Theresa Olesen

Instead of getting birthday presents, Saba raised \$550 on behalf of VIVA to help children with cancer in Singapore.

A little smile to extend life for another mile...

Anish Kumar

As childhood cancer cases grow every year, it seemed to Anish that every third friend knew someone affected by cancer. When his son was born, he wanted to show others that doing little things—such as a smile—can make a big difference in someone's life. Anish raised \$280 in aid of VIVA and donated his hair to support children affected by childhood cancer.

BRINGING YEAR END CHEERS TO CHILDHOOD CANCER PATIENTS



End of year brought new opportunities to spread Christmas cheer to childhood cancer patients and raise public awareness on how they can support survivors and families. In December 2019, VIVA held several activities to brighten up the day for kids undergoing treatment at hospitals in Singapore, and raise funds during the season of giving.



Christmas Carolling with Childhood Cancer Patients 12 Dec / 16 Dec 2019

Together with amazing partners from New Horizon Music Society, the Australian International School (AIS) Parent Choir and our volunteer Belinda Liok, VIVA organised its annual carolling session at paediatric wards across the VIVA University Cancer University Centre at the NUH, the Khoo Teck Puat National University Children's Medical Institute, and at KKH. We enjoyed putting smiles on faces of kids under-going cancer treatment as carollers sang songs and Belinda distributed gifts.

VIVA is grateful to our volunteers for this opportunity to bring cheer to patients during the festive season!



NVPC GIVING WEEK VIVA @ Gardens by the Bay and Volvo 1-7 Dec 2019

VIVA took part in the National Volunteer and Philanthropy Centre (NVPC)'s nationwide Giving Week Campaign, and had the opportunity to share its work with visitors to Gardens by the Bay and to the Volvo Showroom.

We thank NVPC, Gardens by the Bay, and Volvo for the opportunity.



VIVA Teams up with Cosentino! 19 Dec 2019

The Cosentino Group chose VIVA as its beneficiary for its year-end CSR activities. Their employees, partners, and clients came together to contribute gifts for childhood cancer patients and distributed them across children's cancer wards at KKH and NUH!

VIVA thanks the Cosentino Group for bringing joy to kids with cancer during the holiday period and for the opportunity to share about VIVA's work to its network.


VIVA IN THE PRESS



Why Singapore's Wealthiest Are Backing This Lawyer In The Fight Against Childhood Cancer



Grace Chung Forbes Staff
Billionaires



THE STRAITS TIMES

Cellular therapy gives hope to cancer patients



The treatment for leukaemia was developed by Professor Dario Campana of the National University of Singapore.

PUBLISHED AUG 1 2019, 5:00 AM SGT

Vanessa Liu vanessa.liu@sph.com.sg

Two patients who faced almost certain death from an aggressive form of cancer have a new lease of life after undergoing experimental treatment to boost their immune systems.

THE STRAITS TIMES



Hospitals in tie-up to boost children's cancer research in Asia



Viva Foundation for Children with Cancer founder, director, Ho and Dr. The Hong Kong, chairman of St. Jude Children's Research Hospital's research department, speaking during a dinner at the One Hong Kong last night.

PUBLISHED MAR 3 2019, 5:00 AM SGT

St Jude in the US to share knowledge with Spore, China

Barbara barbara.liu@sph.com.sg

An alliance of hospitals in Singapore, China and the United States will collaborate to improve children's cancer research in Asia. Under a memorandum of understanding signed on Friday, experts from St. Jude Children's Research Hospital in the US will share their knowledge and expertise on treating acute lymphoblastic leukaemia (ALL), with leukaemia professionals in Singapore and China.



22:38, 04 Mar 2019

Infant Cancer Care: Cure rates for childhood cancer in Asia get a boost

Updated 22:20, 07 Mar 2019

Share [f](#) [t](#) [v](#) [p](#)



TOP NEWS
Latest
Coronavirus cases worldwide surpass 4.4 million: John Hopkins

03/07/19 07:00:00



中文 / 新聞 / 新聞

新中美机构成立跨境医疗联盟 盼提高亚洲儿童癌症治愈率

综合

来源 / 文 / 综合 / 综合 / 综合

日期 / 2019年3月13日 1:30 AM



海外父母疼爱子女的心，VIVA基金会创始人兼主席（左），以及新加坡儿童癌症研究基金会主席（右）在新闻发布会上，希望提高亚洲儿童癌症治愈率。把本地、中国和美国的研究机构联合起来，建立跨境医疗联盟，提高亚洲儿童癌症治愈率。


字大小 小 中 大

新加坡、中国和美国的主要医疗机构将组成跨境联盟，旗下三家机构会开展更多学术研究和临床试验，提高亚洲儿童癌症治愈率。此外，该联盟还将建立跨境医疗联盟，提高亚洲儿童癌症治愈率。

新加坡、中国和美国的主要医疗机构将组成跨境联盟，旗下三家机构会开展更多学术研究和临床试验，提高亚洲儿童癌症治愈率。此外，该联盟还将建立跨境医疗联盟，提高亚洲儿童癌症治愈率。



PROF DARIO CAMPANA
University of Singapore



NUS Medicine researcher wins Gabbay award for CAR-T Immunotherapy

01 August 2019 | News | By Huihui CB

MUH patients treated using CAR-T immunotherapy now cancer-free



NUS Yong Loo Lin School of Medicine, on 31 July 2019, announced its international award for successful ground-breaking CAR-T cell immunotherapy. The Jacob and Louise Gabbay Award in Biotechnology and Medicine recognise scientists in academia, medicine or industry who work hold outstanding scientific content and significant practical consequences in the biomedical sciences.



US, China can cooperate for a better world

A report from the treatment of children's cancer shows how leaders with the will of mutual interests

ASIA TIMES

ASIA TIMES



On March 1, a memorandum of understanding was signed to boost collaboration on children's cancer research between the US and Asia. The agreement was signed by the parties involved in the research: the US, China, Singapore, and the Asia-Pacific region. The agreement was signed by the parties involved in the research: the US, China, Singapore, and the Asia-Pacific region.

OPEN UP
NEW OPPORTUNITIES
Investment opportunities



S'pore, China & US working together on children's cancer research

Setting aside whatever differences for the sake of the children.

Mothership [f](#) [t](#) [v](#) [p](#)



THE STRAITS TIMES

Patients resistant to chemotherapy found to respond to immunotherapy: trials to begin in January



The treatment was developed by Professor Dario Campana (standing), an expert in advanced cellular therapy from the National University of Singapore Yong Loo Lin School of Medicine. ST PHOTO: JASON QUAY

PUBLISHED JUL 31 2019, 9:28 PM SGT

Vanessa Liu vanessa.liu@sph.com.sg

SINGAPORE - Ten patients who faced almost certain death from an aggressive form of cancer have a new lease on life after undergoing experimental treatment to boost their immune systems.

VIVA IN THE PRESS



- [Hope for high-risk leukaemia patients - The MA-Spore ALL 2010 Study](#)
(Spark Magazine Issue 6, Feb 2019)
- [新中美机构成立跨境医疗联盟 盼提高亚洲儿童癌症治愈率](#)
(联合早报, 2019年3月3日)
- [Hospitals in tie-up to boost children's cancer research in Asia](#)
(The Straits Times, 3 Mar 2019)
- [Infant Cancer Care: Cure rates for childhood cancer in Asia get a boost](#)
(China Global Television Network, 4 Mar 2019)
- [US, China can cooperate for a better world](#)
(Asia Times, 6 Mar 2019)
- [S'pore, China & US working together on children's cancer research](#)
(mothership, 7 Mar 2019)
- [Why Singapore's wealthiest are backing this lawyer in the fight against childhood cancer](#)
(Forbes Asia, 20 Mar 2019)
- [NUS Medicine researcher wins Gabbay award for CAR-T Immunotherapy](#)
(BioSpectrum, 1 Aug 2019)
- [S'porean founder of cancer charity receives award from Shanghai university for contributions to cancer](#)
(Mothership, 12 Aug 2019)
- [House of Hope to be showcased on Asian pediatric oncology meet](#)
(Philippine Information Agency, 21 Sep 2019)
- [City hosts Asian pediatric meeting](#)
(Mindanao Times, 21 Sep 2019)
- [Welcome dinner for pediatric oncologists](#)
(Mindanao Times, 26 Sep 2019)

STATEMENT OF FINANCIAL ACTIVITIES

For the Financial Year Ended 31 December 2019

INCOME

	2019 S\$	2018 S\$
Unrestricted General Funds		
Income from generated funds		
- Voluntary income	2,359,931	2,020,810
- Investment Income	48,061	25,527
- Activities for generating funds	171,322	396,590
- Income from VIVA-KKH Program	-	400,000
Income from charitable activities	515,548	378,013
Other Income	255	4,538
TOTAL INCOME	3,095,117	3,225,523

EXPENDITURES

Cost of generating funds		
- Cost of generating voluntary income	64,322	32,403
Charitable activities	1,602,505	3,193,974
Governance costs	878,438	769,308
TOTAL EXPENDITURES	2,545,265	3,995,685

Net income (expenditure) before tax expense	549,852	(770,162)
--	---------	-----------

Tax expense	-	-
Net (income) expenditure	549,852	(770,162)

Gross transfers between funds	-	-
Net movement in funds	549,852	(770,162)

Reconciliation of funds		
Total funds brought forward	25,072,411	25,842,573
Total funds carried forward ^(A)	25,622,263	25,072,411

^(A) Total funds carried forward

	2019 S\$	2018 S\$
- Available fund balance	5,739,763	4,707,911
- Donated space		
(This asset cannot be monetised)	19,882,500	20,364,500
	25,622,263	25,072,411

Excerpted from the full Audited Financial Report 1 Jan 2019 to 31 Dec 2019, which will be attached separately to this Annual Report.

STATEMENT OF FINANCIAL POSITION

For the Financial Year as at 31 December 2019

	2019 S\$	2018 S\$
Non-Current Assets		
Property and Equipment	19,974,062	20,487,711
Current Assets		
Other receivables and prepayments	157,839	180,614
Cash and cash equivalents	5,594,499	4,479,250
	5,752,338	4,659,864
Current Liabilities		
Accrued Expenses	6,825	1,802
Deposits Received	50,014	52,362
Other payables	47,298	21,000
	104,137	75,164
Net Current Assets	5,648,201	4,584,700
Total Assets Less Current Liabilities	25,622,263	25,072,411
Funds of Charity		
<u>Unrestricted Funds</u>		
General funds ^(A)	25,622,263	25,072,411
TOTAL CHARITY FUNDS	25,622,263	25,072,411
^(A) General Funds		
	2019 S\$	2018 S\$
- Available fund balance	5,739,763	4,707,911
- Donated space		
(This asset cannot be monetised)	19,882,500	20,364,500
	25,622,263	25,072,411

Excerpted from the full Audited Financial Report 1 Jan 2019 to 31 Dec 2019, which will be attached separately to this Annual Report.

STATEMENT OF CASH FLOW

For the Financial Year Ended 31 December 2019

	2019 S\$	2018 S\$
Cash Flows from Operating Activities		
- Net income/(expenditure) before tax expense	549,852	(770,162)
Adjustments for:		
- Depreciation of property and equipment	528,043	523,775
- Interest income	(48,061)	(25,527)
Operating cash flows before changes in working capital	1,029,834	(271,914)
- Other receivables and prepayments	22,775	(30,488)
- Accrued expenses	5,023	(3,760)
- Other payables	26,298	(18,326)
- Deposits received	(2,348)	-
Net cash flows generated from / (used in) operating activities	1,081,582	(287,836)
Cash Flows from Investing Activities		
- Purchase of equipment	(14,394)	(4,270)
- Interest received	48,061	25,527
Net cash flows generated from investing activities	33,667	21,257
Net increase/(decrease) in cash and cash equivalents	1,115,249	(266,579)
Cash and cash equivalents at the beginning of the year	4,479,250	4,745,829
Cash and cash equivalents at the end of the year (Note 14)	5,594,499	4,479,250

Note 14	2019	2018
Cash and Cash Equivalents	S\$	S\$
Cash at bank	3,046,999	1,979,250
Fixed deposits placed with financial institutions	2,547,500	2,500,000
	5,594,499	4,479,250

The effective interest rate on the interest earning bank balance is 1.32% per annum (2018: 0.86%).

The interest rate earned on fixed deposits is at 1.75% (2018: 0.75% to 1.30%) per annum with maturity date of 12 months (2018: 6 to 12 months).

Excerpted from the full Audited Financial Report 1 Jan 2019 to 31 Dec 2019, which will be attached separately to this Annual Report.

COMMUNITY PARTNERSHIP

(Other Charity Funds)

The Charity held donation drives to raise funds for specific projects. As at 31 December 2019, a total funds of S\$78,172,993 was raised by the Charity with a government matching grant of S\$45,065,588.

The details of the funds are divided into three categories as follows:

- (A) specific donations received under the Charity as donation income;
- (B) specific donations co-funded by the Charity and Community Partners; and
- (C) specific donations paid directly to the Community Partners as beneficiaries.

Except as disclosed in Note 18, the details of funds which the donations and the amounts expended below are not reflected in the financial statements of the Charity.

	Cumulative Funds raised as at 31 December 2019		Fund Balances as at 31 December 2019	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
(A) Specific donations received under the Charity as donation income				
Donated space (Note 18)	24,100,000	-	19,882,500	-
Available fund balance (Note 18)	9,333,545	-	5,739,763	-
VIVA-NUS CenTRAL (Note A1)	7,772,099	-	(217,610)	-
Cancer Immunotherapy (Note A2)	1,000,000	-	-	-
(B) Specific donations co-funded by the Charity and Community Partners				
VIVA-KKH Childhood Brain and Solid Cancers Programme (Note B1)	13,257,349	12,951,588	5,312,631	12,951,588
(C) Specific donations paid directly to the Community Partners as beneficiaries				
NUS Children Cancer Centre Fund (Note C1)	2,467,000	4,084,000	1,645,106	3,959,542
NUH Health Research Endowment Fund (Note C2)	7,193,000	3,000,000	2,250,257	3,000,000
VIVA Paediatric Oncology Fund (Note C3)	12,270,000	23,744,000	2,275,146	22,146,568
VIVA Education and Research Fund (Note C4)	780,000	1,286,000	-	1,130,543
	78,172,993	45,065,588	36,887,793	43,188,241

(A) Specific Donations Received under the Charity as Donation Income

The Charity received donations for certain designated funds. These donations were reflected in the financial statements of the Charity as donation income. Subsequently, the Charity donated these to the designated fund managed by the Community Partners. The donated amounts were reflected in the financial statements of the Charity as expenditure incurred for charitable activities. The details of the funds which the amounts expended are not reflected in the financial statements of the Charity are as follows:

(A1) VIVA-NUS Centre for Translational Research in Acute Leukaemia (“CenTRAL”)

	2019		2018	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	244,067	-	440,786	-
- Add/(Less):				
- Donation received	1,264,052	-	844,874	-
- Other income	4,706	-	4,777	-
- Expenditures	(1,730,435)	-	(1,046,370)	-
Balance at 31 December	(217,610)	-	244,067	-
Total Funds Raised by the Charity	7,772,099	-	6,503,341	-

The funds were donated by the Charity to the National University of Singapore to support the advancement of education and research with the establishment of CenTRAL, a state-of-the-art leukaemia research and diagnostic facility with the key objective of improving the cure rates and quality of life of patients with leukaemia and haematologic cancer in Singapore and the Asia region, through accurate leukaemia classification, prediction and determination of treatment response. During the financial year ended 31 December 2019, the Charity received S\$1.26 million of donations from Singapore Tote Board. As at 31 December 2019, these amounts have been subsequently donated by the Charity to CenTRAL.

(A2) Cancer Immunotherapy

	2019		2018	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	-	-	2,195	-
- Less:				
- Expenditures	-	-	(2,195)	-
Balance at 31 December	-	-	-	-
Total Funds Raised by the Charity	1,000,000	-	1,000,000	-

The funds were donated by the Charity to Yong Loo Lin School of Medicine, National University of Singapore, to fund cancer immunotherapy clinical research, specifically to support clinical trials of novel therapies based on immune cells for children and adults with drug resistant cancer. During 2014, a S\$1 million donation was made to NUS by the Charity.

(B) Specific Donations Co-funded by the Charity and Community Partners

The Charity and Community Partners raised funds separately where the contributions by donors were designated for specific purposes. The Charity donations were reflected in the financial statements of the Charity as donation income. Subsequently, when the Charity donated these to the designated funds managed by the Community Partners, the amounts were reflected in the financial statements of the Charity as an expenditure incurred for charitable activities. The details of the funds which the amounts expended were not reflected in the financial statements of the Charity are as follows:

(B1) VIVA-KKH Childhood Brain and Solid Cancers Programme

	2019		2018	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	7,071,425	10,951,528	7,244,264	10,951,418
<u>Add/(Less):</u>				
- Income received	-	-	2,000,000	-
- Additional matched grant	-	2,000,060	-	110
- Expenditures	(1,758,794)	-	(2,172,839)	-
Balance at 31 December	5,312,631	12,951,588	7,071,425	10,951,528
Total Funds Raised by the Charity	13,257,349	12,951,588	13,257,349	10,951,528

The funds were donated by the Charity to KKH Health Fund (formerly known as KKH Health Endowment Fund) used for the advancement of the treatment and cure for children with brain and solid tumours in Singapore and the Asia Pacific region under the VIVA-KKH Childhood Brain and Solid Cancers Programme. This programme focuses on four areas of childhood brain and solid cancers in clinical care, translational research, registry-based population science, and collaborative education and training. During the previous financial year ended 31 December 2018, a S\$2 million donation was made to VIVA-KKH by the Charity.

(C) Specific Donations Paid Directly to Community Partners as Beneficiaries

The Charity raised funds for the following four projects, where the contributions by donors were designated for specific purposes and paid directly to the Community Partners. The details of the funds which the donations and the amounts expended below are not reflected in the financial statements of the Charity are as follows:

(C1) NUS Children Cancer Centre Fund (“CCCCF”)

	2019		2018	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	1,623,461	3,840,136	1,610,089	3,658,357
<u>Add/(Less):</u>				
- Investment income	15,814	242,350	8,391	183,805
- Other income	6,582	-	4,981	-
- Expenditure	(751)	(122,944)	-	(2,026)
Balance at 31 December	1,645,106	3,959,542	1,623,461	3,840,136
Total Funds Raised by the Charity	2,467,000	4,084,000	2,445,000	3,842,000

The funds were donated to the National University of Singapore – Children Cancer Centre Fund to establish a children’s cancer centre, now known as the VIVA-University Children’s Cancer Centre (“VUC3”) at the National University Hospital which will be the centre of excellence for the treatment and cure of childhood cancer particularly leukaemia; the training and hiring of doctors, nurses, technical and administrative personnel from Singapore and the region; clinical and translational research; cellular therapy and stem cell transplantation. The funding is by VIVA Foundation and by Singapore Totalisator Board.

(C2) NUH Health Research Endowment Fund (“HREF”)

	2019		2018	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	2,201,187	3,000,000	2,436,208	3,000,000
<u>Add/(Less):</u>				
- Other income	49,098	-	64,008	-
- Expenditure	(28)	-	(299,029)	-
Balance at 31 December	2,250,257	3,000,000	2,201,187	3,000,000
Total Funds Raised by the Charity	7,193,000	3,000,000	7,144,000	3,000,000

The funds were donated to the National University Hospital to establish the Mrs Lee Kong Chian Memorial Chair, for Director of Advanced Clinical and Translational Research for Childhood Leukaemia and Cellular Therapy under the VIVA Children’s Cancer Programme. The donation of S\$3 million was received from the Lee Foundation, via the VIVA Foundation and was matched by the Ministry of Health with S\$3 million in two payments received on December 2006 and March 2007. The money was used as a bridging loan to support the setting up of the VUC3.

(C3) VIVA Paediatric Oncology Fund (“VPOF”)

	2019		2018	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	2,981,836	21,416,457	3,458,998	20,819,762
<u>Add/(Less):</u>				
- Investment income	-	1,349,821	-	1,047,082
- Other income	38,095	-	36,467	-
- Expenditure	(744,785)	(619,710)	(513,629)	(450,387)
Balance at 31 December	2,275,146	22,146,568	2,981,836	21,416,457
Total Funds Raised by the Charity	12,270,000	23,744,000	12,232,000	22,394,000

The VIVA Paediatric Oncology Fund has been established with an expendable gift of S\$12 million dollars from the Goh Foundation with a matching grant from the Singapore Government to Yong Loo Lin School of Medicine, NUS. The fund is used to advance paediatric oncology including, but not limited to, supporting the VIVA University Children’s Cancer Centre and St. Jude VIVA Children’s cancer programme. This programme aims to expand the services in paediatric oncology at the National University Health System and to establish for strategic research programmes in the following fields: 1) Bone Marrow Transplant, 2) Childhood Leukaemia, 3) Bone Cancer, 4) After-Completion-of-Therapy and to set up a professorship in paediatric oncology.

(C4) VIVA Education and Research Fund (“VERF”)

	2019		2018	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	-	1,106,611	-	1,095,927
<u>Add/(Less):</u>				
- Investment income	-	69,468	-	54,866
- Expenditure	-	(45,536)	-	(44,182)
Balance at 31 December	-	1,130,543	-	1,106,611
Total Funds Raised by the Charity	780,000	1,286,000	780,000	1,217,000

The funds were donated by the Charity to the National University of Singapore, Department of Paediatrics in support of education, training and research in paediatric oncology specifically through projects that are part of the VIVA Children’s Cancer Programme and income and expenses for the Annual St. Jude VIVA Forum in paediatric oncology. In 2013, the fund was closed and the balance of S\$78,448 was refunded to the Charity.

Note 18 Funds of Charity

Unrestricted Funds

	2019 S\$	2018 S\$
General fund		
- Available fund balance	5,739,763	4,707,911
- Donated space (this asset cannot be monetised)	19,882,500	20,364,500
	<u>25,622,263</u>	<u>25,072,411</u>

Movements of the funds during the current and previous financial year are disclosed as follows:

	Unrestricted Funds S\$
Funds balance at 1 January 2019	25,072,411
Total income	3,095,117
Total expenditure	(2,545,265)
Net income	549,852
Funds balance at 31 December 2019	<u>25,622,263</u>
Funds balance at 1 January 2018	25,842,573
Total income	3,225,523
Total expenditure	(3,995,685)
Net expenditure	(770,162)
Funds balance at 31 December 2018	<u>25,072,411</u>

CODE OF GOVERNANCE

COMPLIANCE WITH CODE OF GOVERNANCE

VIVA Foundation constantly works towards compliance with the Charities Act, Charities (Institutions of Public Character) Regulations, Charities Accounting Standards, the Code of Governance for Charities and IPCs and the Personal Data Protection Act, and take steps to address and resolve weakness/es where appropriate.

MANAGING CONFLICT OF INTEREST

VIVA Foundation has in place a policy relating to the management and avoidance of conflict of interests. All Members, Directors and staff are required to sign the prescribed Declaration of Conflict of Interest form when they are appointed and thereafter annually or whenever there is any material change in the information contained in their respective Declarations.

ONLINE GOVERNANCE EVALUATION CHECKLIST (GEC) via CHARITY PORTAL

VIVA Foundation has been submitting the GEC annually via the Charity Portal. These are also available on VIVA's website at www.viva.sg.

RESERVES POLICY

VIVA Foundation has set aside a reserve of \$1 million to provide financial stability and resources for the development of its principal activities. The Board will periodically review the amount of reserves that are required to ensure adequacy in fulfilling the Foundation's obligations.

SALARIES AND RELATED COSTS

No Directors received any remuneration. During the financial year 2018, no staff personnel received an annual remuneration of \$100,000.00 and above. No staff is involved in setting his/her own remuneration.

VIVA discloses that there is no paid staff, being a close member of the family belonging to the Executive Head or a governing board member of the charity, who has received remuneration exceeding \$50,000 during the financial year.

REELECTION OF DIRECTORS

Board of Directors appointed during the financial year were re-elected by the Members at the Annual General Meeting.

VIVA Foundation does not have term limits of Directors/Members as the Board believes that continued contribution by each Director provides benefits to the foundation. Each Director's integrity is not compromised by the long period of service.

The Board decided, with the Members' approval, that Directors who serve in the Board for more than 10 years are retained. All Directors who are over the age of 70 years were re-appointed to hold office until the conclusion of the next Annual General Meeting of the Company pursuant to Section 153(6) of the Companies Act, Chapter 50.

BOARD MEMBERS ATTENDANCE AT MEETINGS

During the year, three (3) meetings were held - 2 Ordinary Board Meetings and 1 Annual General Meeting. A Director who is unable to attend any meeting in person may participate via teleconference.

The Board is satisfied that each Director is committed towards fulfilling the mission of VIVA Foundation. This is evidenced by their respective valuable contributions in many ways despite not attending some or all of the meetings during the year due to prior commitments.

INTERNAL CONTROL AND RISK MANAGEMENT MEASURES

The Board assumes overall responsibility and is fully committed on maintaining a sound system of internal control and risk management that provide reasonable assurance of effective operations and statutory compliance in accordance with the Code of Governance and Charity Accounting Standards.

The Board ensures that there is a sound internal control policies and procedures in place.

The Board constantly reviews, taking into account changes in the regulatory and statutory, these policies and procedures to ensure adequacy and effectiveness.

The Board has also put in place a risk management policy. One of these policies is the implementation of internal controls as part of the day to day operations.

VOLUNTEER MANAGEMENT

VIVA discloses that there are volunteer management processes in place for volunteers.

RELATED PARTY TRANSACTIONS

VIVA Foundation had the following significant transactions with a related party during the financial year 2019, as detailed below:

Related Party Transactions FY 2019	Audited 31 Dec 2019 S\$	Audited 31 Dec 2018 S\$
With Shangri-La Hotel Singapore		
Venue expense	\$75,855	\$79,760
Accommodation expense	\$118,744	\$30,272
TOTAL	\$194,599	\$110,032

BOARD OF DIRECTORS

In 2019, two (2) Ordinary Board Meetings and one (1) Annual General Meeting were held. The Executive Committee* actively oversees the business of VIVA. The VIVA Board of Directors, comprising 12 Directors, serves pro-bono and ensures that VIVA's mission and vision are met.

EXECUTIVE COMMITTEE



**Mrs Jennifer Yeo
(Mdm Leong Lai Peng)**

Founder and Chairman

Senior Consultant, RHTLaw
Advocate & Solicitor, Singapore
Solicitor, England & Wales

Appointed on 6 Feb 2006



Mdm Kuok Oon Kwong

Vice-Chair

Chairman, National Healthcare
Group
Director, Shangri-La Hotel Ltd
Singapore

Appointed on 9 Nov 2007



Mr Tan Wah Yeow

Non-Resident Ambassador to
the Kingdom of Norway

Appointed on 1 Sep 2010



Mr Christopher Wilson

Co-Founder, Water and
Healthcare Foundation

Appointed on 15 Jan 2015



Ms Shulamite N K Khoo

Independent Non-Executive
Director, Kerry Logistics
Network Limited

Appointed on 1 May 2018

BOARD OF DIRECTORS



Mr Kwee Liong Keng
Managing Director,
Pontiac Land

Appointed on 6 Feb 2006



Ms Tan Bee Lan
President,
Columbia China

Appointed on 1 Aug 2014



Mr Gilbert Cheah
Managing Director,
Catalyst Communications

Appointed on 1 Mar 2016



Mr Martino Tan
Managing Editor,
Mothership.sg

Appointed on 1 May 2018



Mdm Yeong Yoon Ying
Director (Special Duties),
Ministry of Communications
and Information

Appointed on 18 Jan 2019



Ms Cynthia Phua
Management Consultant
Former Singapore Member of
Parliament (2001-2011)

Appointed on 17 Jun 2019

MEMBERS

Christina Fu Mrs Christina Ong

Appointed on 6 Feb 2006

Foo-Yo Mie Yoen Theresa

Appointed on 6 Feb 2006

Koh Seow Chuan

Appointed on 28 May 2014

Kuok Oon Kwong

Appointed on 28 May 2014

Kwee Liong Keng

Appointed on 6 Feb 2006

Lee Ming San

Appointed on 28 May 2014

Leong Lai Peng

Appointed on 6 Feb 2006

Tan Wah Yeow

Appointed on 28 May 2014


Wu Lee Betty, Mrs

Appointed on 6 Feb 2006

EXTERNAL ADVISORY BOARD

VIVA's External Advisory Board (EAB) is made up of an international panel of renowned doctors from the global field of cancer care and research. The VIVA Board of Directors seeks strategic advice and views from the EAB with regards to programmes and projects.

The EAB meets in Singapore once a year. At other times of the year, the Board would also call on the EAB for their expert views and thoughts when necessary.



Dr. Ching-Hon Pui, MD
Chairman

American Cancer Society Professor
Chair, Department of Oncology
Co-Leader, Hematological Malignancies Program
Fahad Nassar Al-Rashid Chair of Leukemia Research
Director, China Region, St. Jude Global
St. Jude Children's Research Hospital
Memphis, Tennessee, USA

Appointed on 19 Dec 2006



Dr Rupert Handgretinger, MD
Member

Professor and Chairman, Department of General Paediatrics
and Hematology / Oncology
Children's University Hospital
Tuebingen, GERMANY

Appointed on 7 Dec 2006



Dr Edward Holmes, MD
Member

President and CEO, Sanford Consortium for Regenerative Medicine
Senior Fellow, A*STAR Advisor
National Research Foundation
SINGAPORE

Appointed on 30 Nov 2006



Prof Anjo Veerman, MD
Member

Professor Emeritus, Paediatrics
Vrije Universiteit University Medical Center
Amsterdam, THE NETHERLANDS

Appointed on 18 Dec 2006




TO A HOLISTIC FUTURE FOR SURVIVORS

Since VIVA began in 2006, we have been working towards our mission to save more lives for children with cancer through excellence in research, medical care, and education—embarking on impactful collaborations and exchanges that have paid dividends in improving survival rates for childhood cancer patients.

While our work in these areas continues, VIVA is also moving towards taking a holistic approach towards cancer care by introducing programmes that focus on the physical, mental, and emotional health and well-being of patients and survivors.

We will be launching the VIVA Life Programme, which will bring together collaborators to provide holistic survivorship care for those affected by childhood cancers. It is our belief that care does not end upon discharge from treatment centres, but rather, children and families affected by childhood cancer continue to need care and support in order to enable the child to not just survive, but thrive.

With love,
VIVA Foundation for Children with Cancer



Thank You!

VIVA would like to express our warmest gratitude to all our donors, volunteers and supporters who contributed to our mission in 2019.

We could not have done this without you.



Help us rewrite the future of kids with cancer.

Donate to the **VIVA Foundation**
for Children with Cancer today.

bit.ly/donate2viva



Scan the QR code
with your preferred
banking app to
donate instantly!

Connect with Us

8 Sinaran Drive
#03-01 Novena Specialist
Centre
Singapore 307470



6694 3370
enquiry@viva.sg

www.viva.sg



@VivaFoundation